Have you or your loved ones been diagnosed with alpha-mannosidosis?

You may be eligible to participate in a alpha-mannosidosis clinical trial.

Have you or your loved ones been diagnosed with alpha-mannosidosis? You may be eligible to participate in a alpha-mannosidosis clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Alpha-Mannosidosis Clinical Trial in North Charleston SC
NCT01891422 | Observational

Have you or your loved ones been diagnosed with alpha-mannosidosis?

You may be eligible to participate in a alpha-mannosidosis clinical trial.

Have you or your loved ones been diagnosed with alpha-mannosidosis? You may be eligible to participate in a alpha-mannosidosis clinical trial.

Recruiting

Male & Female

All ages

This study is looking to recruit 100 Participants

The glycoproteinoses are among the most rare and least researched of the lysosomal diseases. The diseases include aspartylglucosaminuria, fucosidosis, galactosialidosis, alpha-mannosidosis, beta-mannosidosis, mucolipidosis II, mucolipidosis III, Schindler disease, and sialidosis. Longitudinal studies of these conditions are needed in order to better define how common the diseases are, identify clinical features which could contribute to early diagnoses, detail progression of the diseases, assess the supportive therapies currently used, and identify potential treatments. Laboratory tests will evaluate metabolic and genetic defects found in participants' blood and urine samples.

Where you'll go

Selected location

Greenwood Genetic Center

Greenwood Genetic Center Change

North Charleston, SC, USA 29418 Map | Learn more
Step 1 of 4: Email
Selected location

Greenwood Genetic Center

North Charleston, SC, USA 29418

Sara Cathey 843-746-1001
scathey@ggc.org


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.